Reimbursement strategy, regulatory pathway, payer vs provider GTM, hiring clinical leadership, fundraising. Founder-level decisions only — never medical, clinical, or patient-care advice.
Should you pursue 510(k), De Novo, full PMA, or a wellness-only positioning? The Regulator and Strategist synths frame the trade-offs — strategic framing, not regulatory advice.
When do you sell to health systems, when do you sell to payers, when do you go DTC? Multi-year revenue patterns and ramp curves debated in one session.
When do you hire a Chief Medical Officer? What do you actually need from a clinical advisory board? The Empath and Strategist work it through.
Healthtech is capital-intensive and slow. The CFO and Investor synths argue the dilution math against the regulatory timeline.
Real questions. Multiple expert perspectives. Every time.
“Should we pursue a 510(k) clearance, or stay positioned as a wellness product for now?”
“When do we hire our first Chief Medical Officer vs continue with clinical advisors?”
“Should we sell into health systems or pivot to a direct-to-payer motion?”
“How do we price an enterprise contract with a 24-month sales cycle?”
“Should we raise a strategic round from a payer, or stay with healthcare-specialist VCs?”
“Is now the right time to pursue a CPT code, or wait until we have stronger outcomes data?”
Each expert thinks independently — they won’t just agree with each other.
The Strategist
Maps competitive dynamics and strategic options across multi-year horizons.
The Regulator
Reads the rules of the field you’re playing on before you commit.
The Lawyer
Flags legal exposure and contract risk before they become incidents.
The CFO
Pressure-tests unit economics, runway, and capital allocation.
The Ethicist
Surfaces second-order consequences and integrity-cost trade-offs.
A synthesized recommendation from your team of experts — not just opinions, but structured analysis.
Moderate Agreement
Key Recommendations
Synthesized Recommendation
Stay in wellness positioning for 9 more months. Use the runway to generate outcomes data with two enterprise pilots, then pursue 510(k) once the evidence supports it. Don't hire the CMO until you've committed to the clearance path.
Full analysis continues with detailed reasoning, trade-offs, and next steps...
Watch Out For
Expert Opinions
“The hardest healthtech decisions aren't clinical — they're commercial. When do you commit to the regulatory path, when do you hire the medical leadership, who do you raise from. A boardroom is where those trade-offs get pressure-tested before the cash burns.”
SynthBoard is for founder business decisions. It does not give medical, clinical, diagnostic, or patient-care advice and is not a substitute for licensed clinicians, lawyers, or regulatory consultants.
Long sales cycles, regulatory gates, payer negotiations. SynthBoard fits the cadence of a business that ships major decisions quarterly, not weekly.
A regulator, a CFO, a strategist, and an ethicist in one room. The trade-offs healthtech founders normally have to assemble across three separate $10K consulting engagements.
Confidential strategy work stays confidential. Sessions are encrypted, never used for external training, and you control who sees them.
The questions people ask before they sign up.
No. SynthBoard is built for founders making business decisions about healthtech companies — hiring, fundraising, GTM, regulatory strategy. It does not provide medical, clinical, diagnostic, or treatment advice, and is not a substitute for licensed clinicians or healthcare professionals.
No. The Regulator synth helps you frame the strategic shape of a regulatory decision — when to pursue clearance, what to weigh, what to ask. The actual regulatory submission and primary-source compliance work stays with your specialist consultants and counsel.
Both. DTx founders use it heavily for the FDA pathway decision, the reimbursement strategy debate, and the clinical evidence vs commercial-traction trade-off. Broader healthtech uses it for the same hiring, fundraising, and GTM calls.
You can describe a proposed or pending reimbursement change in your own words and the boardroom will pressure-test what it means for your model. It won't cite primary regulatory text — that's your healthcare counsel's domain.
They're different instruments. Your clinical advisory board gives you scientific and clinical guidance. SynthBoard pressure-tests the founder-level business decisions a clinical board isn't set up to debate — pricing, partner selection, fundraising strategy.
SynthBoard is built for founder strategy work, not for patient data. Do not paste PHI (protected health information) into sessions. The platform is encrypted and confidential for strategic founder content, but it is not a HIPAA-covered entity or business associate.
Adjacent decisions, audiences, and methods inside SynthBoard.
Adjacent industry — same regulated-business decision shape.
ExploreMost healthtech is enterprise sale — the broader motion applies.
ExploreCapital-intensive, long-cycle businesses need this debate quarterly.
ExploreThe CMO, Chief Compliance Officer, and Chief Commercial Officer calls.
ExploreA persistent boardroom across a multi-year regulatory journey.
ExploreSurface the failure modes before you commit capital to a regulatory bet.
Explore250 bonus credits at signup. 150 free every month. No card required.